Stocks Listing
CGEN.TA

Compugen Ltd.

Share
CGEN.TA
$0.89 2.15%Last Updated Sep 22 2022 01:56 PM
1D Low / 1D High
Low:$0.89
High:$0.92
1D
2.15%
5D
8.08 %
30D
27.78 %
BulletPurple
Market Cap
$790,767
3.11 %
790.8 K
BulletBlue
Volume 1D
134,190
-
134.2 K
BulletOrange
Circulating Supply
887,958 CGEN.TA
888 K

Price Chart

1D
5D
1M
6M
YTD
1Y
MAX
About

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Read More

Historical data

1D
5D
1M
6M
1Y
MAX
Day
Open - Close
Low/High
Volume
Market Cap
Show More
Market Status
Closed
TLV
Tel-Aviv Stock Exchange
ISR
Opens in
16 hours, 36 minutes
Working Hours
Mon-Thu, 06:59 AM - 02:14 PM
Timezone
GMT+0